VISIDERM

This brand name is authorized in Nigeria.

Active ingredients

The drug VISIDERM contains a combination of these active pharmaceutical ingredients (APIs):

1	Betamethasone UNII 9842X06Q6M - BETAMETHASONE
	Betamethasone is a glucocorticoid which is about eight to ten times as active as prednisolone on a weight-for-weight basis. Betamethasone has anti-inflammatory, antipruritic, and vasoconstrictive properties.
	Read more about Betamethasone
2	Tolnaftate UNII 06KB629TKV - TOLNAFTATE
	Read more about Tolnaftate
3	Gentamicin UNII T6Z9V48IKG - GENTAMICIN
	Gentamicin is usually bactericidal in action. Although the exact mechanism of action has not been fully elucidated, the drug appears to inhibit protein synthesis in susceptible bacteria by irreversibly binding to 30S ribosomal subunits.
	Read more about Gentamicin
4	Clioquinol UNII 7BHQ856EJ5 - CLIOQUINOL
	Read more about Clioquinol

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-6748	Cream	VISIDERM CREAM CREAM 0.643mg; 1mg; 10mg; 10mg 1X30G	VISIDERM CREAM BETAMETHASONE DIPROPIONATE 0.643MG, GENTAMICIN SULFATE 1MG, TOLNAFATE 10MG, IODOCHLORHYDROXYQUINONE 10MG BETAMETHASONE DIPROPIONATE 0.643MG, GENTAMICIN SULFATE 1MG, TOLNAFATE 10MG, IODOCHLORHYDROXYQUINONE 10MG B4-6748 Drugs Imported Products 1X30G Prescription Only Medicine (POM) 16/09/2022 ELBE PHARMA NIGERIA LIMITED, 1, AFRICAN CHURCH CLOSE, OFF COKER ROAD, ILUPEJU, LAGOS STATE, NIGERIA. 8069718539 elbepharma.rgn@gmail.com KREMOINT PHARMA LIMITED, PLOT NO. B-8 ADDITIONAL AMBERNATH MIDC AMBERNATH (E) DIST THANE 421506, INDIA, India	26/04/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D07CC01	Betamethasone and antibiotics	D Dermatologicals → D07 Corticosteroids, dermatological preparations → D07C Corticosteroids, combinations with antibiotics → D07CC Corticosteroids, potent, combinations with antibiotics
Discover more medicines within D07CC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	B4-6748, B4-9265